ClearPoint Neuro, Inc.

Name: ClearPoint Neuro, Inc. standardized financial statements, quarterly
Creator: Listed

CLPTNasdaqCIK 1285550HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$12.1m, Q3 FY2026

Operating income−$6.3m, Q3 FY2026

Net income−$7.5m, Q3 FY2026

ClearPoint Neuro, Inc., income statement, quarterly
Line item	Unit	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Revenue	$m	6.8	7.6	7.9	8.1	7.8	8.5	9.2	8.9	10.4	12.1	10.9	12.1
Cost of revenue	$m	2.8	3.1	2.9	3.3	3.0	3.4	3.7	3.3	4.0	4.4	4.2	5.0
Gross profit	$m	4.0	4.5	5.0	4.8	4.8	5.1	5.6	5.6	6.4	7.8	6.7	7.1
Research and development	$m	2.7	2.6	3.1	3.3	3.3	3.4	3.8	3.5	3.2	4.5	4.6	4.0
Selling, general and administrative	$m	2.7	2.8	2.8	3.1	3.3	4.1	3.4	3.6	5.4	5.0	5.6	3.8
Operating income	$m	(4.7)	(4.2)	(4.7)	(5.2)	(5.6)	(6.2)	(5.7)	(5.3)	(7.0)	(8.5)	(10.2)	(6.3)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	0.0	0.4	0.9	1.1	1.4	1.4	1.4
Income tax	$m	not reported	0.0	0.0	0.0	(0.0)	0.0	0.0	0.0	0.0	0.0	(0.0)	(0.0)
Net income	$m	(4.6)	(4.1)	(4.4)	(5.0)	(5.4)	(6.0)	(5.8)	(5.9)	(7.8)	(9.6)	(11.3)	(7.5)
Diluted EPS	$ per share	not reported	(0.16)	(0.16)	(0.18)	not reported	(0.22)	(0.21)	(0.21)	not reported	(0.32)	(0.38)	(0.24)
Basic EPS	$ per share	not reported	(0.16)	(0.16)	(0.18)	not reported	(0.22)	(0.21)	(0.21)	not reported	(0.32)	(0.38)	(0.24)

Balance sheet

Cash and equivalents$46.2m, Q3 FY2026

Long-term debt$50.8m, Q3 FY2026

Shareholders' equity$27.3m, Q3 FY2026

ClearPoint Neuro, Inc., balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Cash and equivalents	$m	23.1	35.4	32.8	21.6	20.1	12.4	41.5	38.2	45.9	35.6	29.4	46.2
Current assets	$m	36.2	47.6	46.6	34.3	33.4	24.2	54.0	51.3	63.6	54.9	48.9	66.7
Total assets	$m	42.7	53.6	52.6	40.2	39.2	30.1	62.9	60.4	97.7	93.4	86.7	113
Current liabilities	$m	7.4	15.2	16.7	7.6	10.4	6.9	7.4	8.1	10.8	9.5	10.3	9.9
Total liabilities	$m	21.5	19.1	20.4	11.2	13.8	10.1	43.1	44.5	69.7	74.6	76.0	85.5
Long-term debt	$m	9.9	10.0	10.0	not reported	not reported	not reported	28.8	29.2	49.1	49.6	50.2	50.8
Shareholders' equity	$m	21.2	34.6	32.1	29.0	25.4	20.0	19.7	15.9	28.0	18.8	10.8	27.3

Cash flow

Operating cash flow−$20.1m, Q3 FY2026

Capital expenditure$137.0k, Q3 FY2026

ClearPoint Neuro, Inc., cash flow, quarterly
Line item	Unit	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Operating cash flow	$m	(1.2)	(3.8)	(2.7)	(1.2)	(1.2)	(6.2)	(2.6)	(3.1)	(12.1)	(8.0)	(7.0)	(20.1)
Capital expenditure	$m	0.0	0.0	0.0	0.0	0.3	0.2	0.1	0.2	0.0	0.6	0.2	0.1

Diluted shares (weighted)30.98m, Q3 FY2026

ClearPoint Neuro, Inc., shares, quarterly
Line item	Unit	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Diluted shares (weighted)	m shares	24.6	24.6	24.6	25.5	27.5	27.6	27.7	28.3	28.4	29.5	30.2	31.0

Shares outstanding: 32.05m at Oct 21, 2026, from the cover of the 10-Q filed Oct 28, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 05:15 ET. Listed shows no prices and gives no investment advice.